The Correlation Between Tenosynovitis Pattern on Two-Phase Bone Scintigraphy and Clinical Manifestation in Patients with Suspected Rheumatoid Arthritis
- 25 Downloads
To investigate the correlation between the tenosynovitis pattern on two-phase bone scintigraphy (2P-BS) and clinical manifestation in patients with suspected rheumatoid arthritis (RA).
2P-BS including technetium–99m-methylene diphosphonate blood pool and bone phase imaging in 402 consecutive patients with clinically suspected RA were retrospectively reviewed. According to 2010 RA Classification Criteria, patients were grouped as RA and non-RA. Visual assessment of all fingers, toes, wrists, and ankles on 2P-BS was performed. Clinical suspected tenosynovitis was evaluated on physical examination. Rheumatoid factor, anti-cyclic citrullinated protein antibody, C-reactive protein, and estimated sedimentation rate were obtained. Radiographic findings were also used to define early and established arthritis.
Tenosynovitis pattern was detected in 12.7% (51/402 patients) on 2P-BS. A total of 94.1% (48/51) were diagnosed as RA vs. 5.9% (3/51) as non-RA. Of the 48 RA patients with positive 2P-BS finding, 85.4% (41/48) had early arthritis and 14.6% (7/48) had established arthritis. On physical examination, tenosynovitis was suspected in 21.9% (88/402). A total of 56.8% (50/88) belonged to the RA group and 43.2% (38/88) to the non-RA group. The tenosynovitis pattern of 2P-BS and physical examination showed statistical difference and moderate agreement. The positive tenosynovitis pattern on 2P-BS represented up to 26.408 of odds ratio which was highest among the RA-associated factors.
Tenosynovitis pattern on 2P-BS was more commonly detected in the RA group and was more frequently associated with early arthritis pattern. Therefore, 2P-BS could give additional information for the detection of subclinical tenosynovitis in early or preclinical RA patients.
KeywordsTenosynovitis Bone scintigraphy MDP Rheumatoid arthritis
Compliance with Ethical Standards
Conflict of Interest
Hyung Jin Choi, Soo Jin Lee, Ji Young Kim, Yoon-Kyoung Sung, and Yun Young Choi declare no conflict of interest.
All procedures followed were performed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013.
The study design of the retrospective analysis and exemption of informed consent were approved by the Institutional Review Board of Hanyang University Medical Center (HYUH 2018-11-001).
- 8.Emery P, Seto Y. Role of biologics in early arthritis. Clin Exp Rheumatol. 2003;21:S191–4.Google Scholar
- 9.Hammer HB, Kvien TK, Terslev L. Tenosynovitis in rheumatoid arthritis patients on biologic treatment: involvement and sensitivity to change compared to joint inflammation. Clin Exp Rheumatol. 2017;35:959–65.Google Scholar
- 14.Boutry N, Larde A, Lapegue F, Solau-Gervais E, Flipo RM, Cotten A. Magnetic resonance imaging appearance of the hands and feet in patients with early rheumatoid arthritis. J Rheumatol. 2003;30:671–9.Google Scholar
- 15.Danielsen MA. Ultrasonography for diagnosis, monitoring and treatment of tenosynovitis in patients with rheumatoid arthritis. Dan Med J. 2018;65.Google Scholar
- 20.Zabotti A, Salvin S, Quartuccio L, De Vita S. Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands. Clin Exp Rheumatol. 2016;34:459–65.Google Scholar
- 21.Stein F, Miale A Jr, Stein A. Enhanced diagnosis of hand and wrist disorders by triple phase radionuclide bone imaging. Bull Hosp Jt Dis Orthop Inst. 1984;44:477–84.Google Scholar
- 28.Wikimedia Commons contributors. Gray’s Anatomy plates, Wikimedia Commons, the free media repository. https://commons.wikimedia.org/wiki/Gray%27s_Anatomy_plates. Accessed 6 Dec 2018.
- 33.Jain A, Nanchahal J, Troeberg L, Green P, Brennan F. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum. 2001;44:1754–60.CrossRefGoogle Scholar